β2 Adrenergic Receptor Polymorphisms and COPD Exacerbations: a Complicated Story

Overview

Journal Thorax

Date 2019 Sep 5

PMID 31481632

Citations 1

Authors

Wassim W Labaki

MeiLan K Han

Affiliations

Soon will be listed here.

Citing Articles

The Combination of Hemogram Indexes to Predict Exacerbation in Stable Chronic Obstructive Pulmonary Disease.

Liu X, Ge H, Feng X, Hang J, Zhang F, Jin X Front Med (Lausanne). 2020; 7:572435.

PMID: 33381510 PMC: 7769039. DOI: 10.3389/fmed.2020.572435.

References

Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

Green S, Turki J, Innis M, Liggett S . Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994; 33(32):9414-9. DOI: 10.1021/bi00198a006. View

Rabe K, Fabbri L, Israel E, Kogler H, Riemann K, Schmidt H . Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med. 2014; 2(1):44-53. DOI: 10.1016/S2213-2600(13)70248-0. View

Ingebrigtsen T, Thomsen S, Vestbo J, van der Sluis S, Kyvik K, Silverman E . Genetic influences on Chronic Obstructive Pulmonary Disease - a twin study. Respir Med. 2010; 104(12):1890-5. DOI: 10.1016/j.rmed.2010.05.004. View

Bowler R, Kim V, Regan E, Williams A, Santorico S, Make B . Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest. 2014; 146(4):941-950. PMC: 4188150. DOI: 10.1378/chest.13-2946. View

Soler-Cataluna J, Martinez-Garcia M, Roman Sanchez P, Salcedo E, Navarro M, Ochando R . Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60(11):925-31. PMC: 1747235. DOI: 10.1136/thx.2005.040527. View

Al-Jameil N, Hassan A, Hassanato R, Isac S, Otaiby M, Al-Shareef F . The prevalence of PI*S and PI*Z SERPINA1 alleles in healthy individuals and COPD patients in Saudi Arabia: A case-control study. Medicine (Baltimore). 2017; 96(42):e8320. PMC: 5662408. DOI: 10.1097/MD.0000000000008320. View

Ingebrigtsen T, Vestbo J, Rode L, Marott J, Lange P, Nordestgaard B . β-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study. Thorax. 2019; 74(10):934-940. DOI: 10.1136/thoraxjnl-2018-212340. View

Han M, Quibrera P, Carretta E, Barr R, Bleecker E, Bowler R . Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017; 5(8):619-626. PMC: 5558856. DOI: 10.1016/S2213-2600(17)30207-2. View

10.

Wain L, Shrine N, Artigas M, Erzurumluoglu A, Noyvert B, Bossini-Castillo L . Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. Nat Genet. 2017; 49(3):416-425. PMC: 5326681. DOI: 10.1038/ng.3787. View

11.

Cho M, McDonald M, Zhou X, Mattheisen M, Castaldi P, Hersh C . Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. Lancet Respir Med. 2014; 2(3):214-25. PMC: 4176924. DOI: 10.1016/S2213-2600(14)70002-5. View

12.

Dransfield M, Kunisaki K, Strand M, Anzueto A, Bhatt S, Bowler R . Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016; 195(3):324-330. PMC: 5328181. DOI: 10.1164/rccm.201605-1014OC. View

13.

Bleecker E, Meyers D, Bailey W, Sims A, Bujac S, Goldman M . ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest. 2012; 142(2):320-328. PMC: 3425335. DOI: 10.1378/chest.11-1655. View